Majesco Entertainment Company (NASDAQ:COOL) CFO John Stetson purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 18th. The shares were bought at an average cost of $23.49 per share, with a total value of $23,490.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Majesco Entertainment Company (NASDAQ COOL) traded up 3.55% during trading on Friday, hitting $24.77. The stock had a trading volume of 35,257 shares. Majesco Entertainment Company has a 12-month low of $2.61 and a 12-month high of $32.63. The firm has a 50 day moving average price of $26.42 and a 200 day moving average price of $21.04. The firm’s market cap is $143.64 million.
ILLEGAL ACTIVITY NOTICE: “John Stetson Buys 1,000 Shares of Majesco Entertainment Company (NASDAQ:COOL) Stock” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/28/majesco-entertainment-company-cool-cfo-john-stetson-acquires-1000-shares-of-stock.html.
A hedge fund recently raised its stake in Majesco Entertainment stock. Wells Fargo & Company MN increased its holdings in shares of Majesco Entertainment Company (NASDAQ:COOL) by 41.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,650 shares of the company’s stock after acquiring an additional 1,650 shares during the period. Wells Fargo & Company MN owned approximately 0.11% of Majesco Entertainment worth $131,000 as of its most recent SEC filing. Institutional investors own 7.88% of the company’s stock.
About Majesco Entertainment
PolarityTE, Inc, formerly Majesco Entertainment Company, is the owner of patent applications and know-how related to regenerative medicine and tissue engineering, as well as software applications used in diagnosis and treatment related to regenerative medicine. The Company seeks to develop and obtain regulatory approval for technology that will utilize a patient’s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves.
Receive News & Ratings for Majesco Entertainment Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Majesco Entertainment Company and related companies with MarketBeat.com's FREE daily email newsletter.